Fig. 3: Resolution of heterogeneity in outcomes using Molecular Group classification within WHO grades.
From: Molecular classification to refine surgical and radiotherapeutic decision-making in meningioma
a, Heatmap of CNVs organized by chromosome number (vertical) and Molecular Group (MG) (horizontal) called by DNA methylation in the complete cohort of retrospective meningioma cases with available DNA methylation data. b, Principal component analysis (PCA) of all meningiomas based on DNA methylation, colored and circled by their respective MG. c–e, Molecular reclassification of meningiomas into each of the four MGs, including the proportion of cases within each respective WHO grade belonging to each MG. f–h, PFS outcomes stratified by MG of meningiomas within each WHO grade: WHO grade 1 (f), grade 2 (g) and grade 3 (h). i–l, PFS outcomes stratified by EOR in molecularly defined Immunogenic (i), NF2-wt (j), Hypermetabolic (k) and Proliferative (l) meningioma cases, with PFS groups stratified based on treatment modality (EOR and receipt of adjuvant RT). Inset shows the P values from the pairwise log-rank test between groups with Benjamini–Hochberg correction for multiple comparisons. PC, principal component.